UroGen Pharma Ltd.
URGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $457 | $433 | $202 | $213 |
| - Cash | $172 | $95 | $55 | $44 |
| + Debt | $123 | $100 | $100 | $0 |
| Enterprise Value | $408 | $438 | $247 | $169 |
| Revenue | $90 | $83 | $64 | $48 |
| % Growth | 9.3% | 28.5% | 34% | – |
| Gross Profit | $82 | $73 | $57 | $43 |
| % Margin | 90.2% | 88.7% | 88.1% | 89.3% |
| EBITDA | -$95 | -$60 | -$76 | -$91 |
| % Margin | -105.5% | -73% | -118.4% | -190.4% |
| Net Income | -$127 | -$102 | -$110 | -$111 |
| % Margin | -140.4% | -123.6% | -170.6% | -230.7% |
| EPS Diluted | -2.96 | -3.55 | -4.79 | -4.96 |
| % Growth | 16.6% | 25.9% | 3.4% | – |
| Operating Cash Flow | -$97 | -$76 | -$88 | -$85 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$97 | -$77 | -$88 | -$86 |